Basic and clinical studies on ceftazidime in the pediatric field

Y. Sato, S. Iwata, Y. Iwasaki, H. Akita, T. Murai, S. Hayano, R. Wakabayashi, K. Sunakawa, T. Oikawa, M. Osano

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Basic and clinical studies were made on ceftazidime (CAZ) in the pediatric field, and the following results were obtained. The antibacterial activity of CAZ against clinically isolated and maintained strains was examined. CAZ was unequivocally more active than CEZ and CMZ against gram-negative rods, with MIC distribution similar to that of CTX, except for that for P. aeruginosa. The MIC of CAZ was lower than that of CTX for P. aeruginosa. Compared with the MICs of CEZ, CMZ and CTX, CAZ showed slightly higher MICs for gram-positive bacteria. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a one shot intravenous injection of 10 mg/kg of CAZ were 64.9, 36.9, 28,3, 14.7, 4.92 and 2.42 μg/ml, respectively, with a half-life of 1.27 hours. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a 1-hour drip infusion of 10 mg/kg of CAZ were 16.6, 24.5, 41.4, 17.1, 5.38 and 2.62 μg/ml, respectively, with a half-life of 1.28 hours. The blood concentrations of CAZ, to 0.25, 0.5, 1, 2, 4 and 6 hours after a one shot intravenous injection of 20 mg/kg of CAZ were 73.1, 60.8, 39.3, 17.3, 8.23 and 4.45 μg/ml, respectively, with a half-life of 1.42 hours. The blood concentrations of CAZ, at 0.5, 1, 2, 4 and 6 hours after a 1-hour drip infusion of 20 mg/kg of CAZ were 55.1, 69.0, 32.1, 11.4 and 4.56 μg/ml respectively, with a half-life of 1.27 hours. Urinary recovery rate of CAZ during the first 6 hours after a one shot intravenous injection of 10 mg/kg of CAZ was 86.7%. CAZ was administered to 17 childen with infections, and the clinical response was excellent or good in 94%. CAZ was bacteriologically effective in 14 patients, all bacteria having been eradicated in them. The bacteria were E. coli in 10 patients, H. influenzae in 2, P. aeruginosa in 1 and S. pneumoniae in 1. As for side effects, slight elevation in GOT was observed in 1 case and eosinophilia in another case.

Original languageEnglish
Pages (from-to)389-406
Number of pages18
JournalJapanese Journal of Antibiotics
Volume37
Issue number3
Publication statusPublished - 1984

Fingerprint

Ceftazidime
Pediatrics
Half-Life
Intravenous Injections
Clinical Studies
Intravenous Infusions
Bacteria
Eosinophilia
Gram-Positive Bacteria

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Sato, Y., Iwata, S., Iwasaki, Y., Akita, H., Murai, T., Hayano, S., ... Osano, M. (1984). Basic and clinical studies on ceftazidime in the pediatric field. Japanese Journal of Antibiotics, 37(3), 389-406.

Basic and clinical studies on ceftazidime in the pediatric field. / Sato, Y.; Iwata, S.; Iwasaki, Y.; Akita, H.; Murai, T.; Hayano, S.; Wakabayashi, R.; Sunakawa, K.; Oikawa, T.; Osano, M.

In: Japanese Journal of Antibiotics, Vol. 37, No. 3, 1984, p. 389-406.

Research output: Contribution to journalArticle

Sato, Y, Iwata, S, Iwasaki, Y, Akita, H, Murai, T, Hayano, S, Wakabayashi, R, Sunakawa, K, Oikawa, T & Osano, M 1984, 'Basic and clinical studies on ceftazidime in the pediatric field', Japanese Journal of Antibiotics, vol. 37, no. 3, pp. 389-406.
Sato Y, Iwata S, Iwasaki Y, Akita H, Murai T, Hayano S et al. Basic and clinical studies on ceftazidime in the pediatric field. Japanese Journal of Antibiotics. 1984;37(3):389-406.
Sato, Y. ; Iwata, S. ; Iwasaki, Y. ; Akita, H. ; Murai, T. ; Hayano, S. ; Wakabayashi, R. ; Sunakawa, K. ; Oikawa, T. ; Osano, M. / Basic and clinical studies on ceftazidime in the pediatric field. In: Japanese Journal of Antibiotics. 1984 ; Vol. 37, No. 3. pp. 389-406.
@article{8ad1c5d49bf34adf8cd287aadc1d692a,
title = "Basic and clinical studies on ceftazidime in the pediatric field",
abstract = "Basic and clinical studies were made on ceftazidime (CAZ) in the pediatric field, and the following results were obtained. The antibacterial activity of CAZ against clinically isolated and maintained strains was examined. CAZ was unequivocally more active than CEZ and CMZ against gram-negative rods, with MIC distribution similar to that of CTX, except for that for P. aeruginosa. The MIC of CAZ was lower than that of CTX for P. aeruginosa. Compared with the MICs of CEZ, CMZ and CTX, CAZ showed slightly higher MICs for gram-positive bacteria. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a one shot intravenous injection of 10 mg/kg of CAZ were 64.9, 36.9, 28,3, 14.7, 4.92 and 2.42 μg/ml, respectively, with a half-life of 1.27 hours. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a 1-hour drip infusion of 10 mg/kg of CAZ were 16.6, 24.5, 41.4, 17.1, 5.38 and 2.62 μg/ml, respectively, with a half-life of 1.28 hours. The blood concentrations of CAZ, to 0.25, 0.5, 1, 2, 4 and 6 hours after a one shot intravenous injection of 20 mg/kg of CAZ were 73.1, 60.8, 39.3, 17.3, 8.23 and 4.45 μg/ml, respectively, with a half-life of 1.42 hours. The blood concentrations of CAZ, at 0.5, 1, 2, 4 and 6 hours after a 1-hour drip infusion of 20 mg/kg of CAZ were 55.1, 69.0, 32.1, 11.4 and 4.56 μg/ml respectively, with a half-life of 1.27 hours. Urinary recovery rate of CAZ during the first 6 hours after a one shot intravenous injection of 10 mg/kg of CAZ was 86.7{\%}. CAZ was administered to 17 childen with infections, and the clinical response was excellent or good in 94{\%}. CAZ was bacteriologically effective in 14 patients, all bacteria having been eradicated in them. The bacteria were E. coli in 10 patients, H. influenzae in 2, P. aeruginosa in 1 and S. pneumoniae in 1. As for side effects, slight elevation in GOT was observed in 1 case and eosinophilia in another case.",
author = "Y. Sato and S. Iwata and Y. Iwasaki and H. Akita and T. Murai and S. Hayano and R. Wakabayashi and K. Sunakawa and T. Oikawa and M. Osano",
year = "1984",
language = "English",
volume = "37",
pages = "389--406",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "3",

}

TY - JOUR

T1 - Basic and clinical studies on ceftazidime in the pediatric field

AU - Sato, Y.

AU - Iwata, S.

AU - Iwasaki, Y.

AU - Akita, H.

AU - Murai, T.

AU - Hayano, S.

AU - Wakabayashi, R.

AU - Sunakawa, K.

AU - Oikawa, T.

AU - Osano, M.

PY - 1984

Y1 - 1984

N2 - Basic and clinical studies were made on ceftazidime (CAZ) in the pediatric field, and the following results were obtained. The antibacterial activity of CAZ against clinically isolated and maintained strains was examined. CAZ was unequivocally more active than CEZ and CMZ against gram-negative rods, with MIC distribution similar to that of CTX, except for that for P. aeruginosa. The MIC of CAZ was lower than that of CTX for P. aeruginosa. Compared with the MICs of CEZ, CMZ and CTX, CAZ showed slightly higher MICs for gram-positive bacteria. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a one shot intravenous injection of 10 mg/kg of CAZ were 64.9, 36.9, 28,3, 14.7, 4.92 and 2.42 μg/ml, respectively, with a half-life of 1.27 hours. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a 1-hour drip infusion of 10 mg/kg of CAZ were 16.6, 24.5, 41.4, 17.1, 5.38 and 2.62 μg/ml, respectively, with a half-life of 1.28 hours. The blood concentrations of CAZ, to 0.25, 0.5, 1, 2, 4 and 6 hours after a one shot intravenous injection of 20 mg/kg of CAZ were 73.1, 60.8, 39.3, 17.3, 8.23 and 4.45 μg/ml, respectively, with a half-life of 1.42 hours. The blood concentrations of CAZ, at 0.5, 1, 2, 4 and 6 hours after a 1-hour drip infusion of 20 mg/kg of CAZ were 55.1, 69.0, 32.1, 11.4 and 4.56 μg/ml respectively, with a half-life of 1.27 hours. Urinary recovery rate of CAZ during the first 6 hours after a one shot intravenous injection of 10 mg/kg of CAZ was 86.7%. CAZ was administered to 17 childen with infections, and the clinical response was excellent or good in 94%. CAZ was bacteriologically effective in 14 patients, all bacteria having been eradicated in them. The bacteria were E. coli in 10 patients, H. influenzae in 2, P. aeruginosa in 1 and S. pneumoniae in 1. As for side effects, slight elevation in GOT was observed in 1 case and eosinophilia in another case.

AB - Basic and clinical studies were made on ceftazidime (CAZ) in the pediatric field, and the following results were obtained. The antibacterial activity of CAZ against clinically isolated and maintained strains was examined. CAZ was unequivocally more active than CEZ and CMZ against gram-negative rods, with MIC distribution similar to that of CTX, except for that for P. aeruginosa. The MIC of CAZ was lower than that of CTX for P. aeruginosa. Compared with the MICs of CEZ, CMZ and CTX, CAZ showed slightly higher MICs for gram-positive bacteria. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a one shot intravenous injection of 10 mg/kg of CAZ were 64.9, 36.9, 28,3, 14.7, 4.92 and 2.42 μg/ml, respectively, with a half-life of 1.27 hours. The blood concentrations of CAZ, at 0.25, 0.5, 1, 2, 4 and 6 hours after a 1-hour drip infusion of 10 mg/kg of CAZ were 16.6, 24.5, 41.4, 17.1, 5.38 and 2.62 μg/ml, respectively, with a half-life of 1.28 hours. The blood concentrations of CAZ, to 0.25, 0.5, 1, 2, 4 and 6 hours after a one shot intravenous injection of 20 mg/kg of CAZ were 73.1, 60.8, 39.3, 17.3, 8.23 and 4.45 μg/ml, respectively, with a half-life of 1.42 hours. The blood concentrations of CAZ, at 0.5, 1, 2, 4 and 6 hours after a 1-hour drip infusion of 20 mg/kg of CAZ were 55.1, 69.0, 32.1, 11.4 and 4.56 μg/ml respectively, with a half-life of 1.27 hours. Urinary recovery rate of CAZ during the first 6 hours after a one shot intravenous injection of 10 mg/kg of CAZ was 86.7%. CAZ was administered to 17 childen with infections, and the clinical response was excellent or good in 94%. CAZ was bacteriologically effective in 14 patients, all bacteria having been eradicated in them. The bacteria were E. coli in 10 patients, H. influenzae in 2, P. aeruginosa in 1 and S. pneumoniae in 1. As for side effects, slight elevation in GOT was observed in 1 case and eosinophilia in another case.

UR - http://www.scopus.com/inward/record.url?scp=0021681174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021681174&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 389

EP - 406

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 3

ER -